AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02756572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT02756572 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT02756572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan Hydrochloride
Description: Given IV
Study NCT03380065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Late deflation of TR band
Description: 1. First 3ml of air is removed after TWO hour of sheath removal. Then, 3ml of air is removed every 15minutes.~2. Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 3ml of air is pushed back into the device until bleeding stops. Then a gap of 15minutes is observed for the next deflation.
Study NCT03380065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Early deflation of TR band
Description: 1. First 2ml of air is removed from the band ONE hour after sheath removal. Then, 2ml of air is removed every 30minutes.~2. Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 2ml of air should be pushed back into the device until bleeding stops. Then wait for another 30minutes for the next deflation.
Study NCT01741987 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Optive ®
Description: instilation of 1 drop each eye 4 times per day
Study NCT01741987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Tears ®
Description: instilation of eye drop 4 times a day (qid)
Study NCT03364101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Composition of the placebo is 100% organic rice flour, manufactured at a facility New York State licensed to produce pharmaceuticals. Capsules will be instructed to commence on day 7 of the study after baseline appointment.
Study NCT03364101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: POWEROFF Capsule
Description: blend of California Poppy Aerial Part Extract, L-Cystine, L-Theanine,GABA (proprietary Phosphatidylcholine-Palmitic Acid-Oleic Acid Complex), 5-HTP, Magnolia Officinalis Bark Extract, Glycine, Melatonin with 0.5mg of Vitamin B6 (as pyridoxal-5-phosphate).
Study NCT02330497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation under EUS
Description: Pancreatic radiofrequency ablation under endoscopic ultrasonography guidance Procedure under general anesthesia Punction of the pancreatic lesion and aspiration of the liquid if present / then thermal ablation with a 18G needle (50 W during 10 secondes) - only one session
Study NCT03732664 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab
Description: One to four doses of anti-PD-1 or anti-PD-L1 antibody will be administered to enrolled patients on Day -56, Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days.
Study NCT01615458 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Care Model for Mood Disorders
Description: CCM includes (1) patient self-management enhancement focused on promoting healthy lifestyles as coping strategies to minimize the negative impact of depressive, manic, and other affective symptoms; (2) provider support for evidence-based decision-making; and (3) enhanced access and continuity for anticipatory rather than reactive care.
Study NCT04765930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Q-switched nd:YAG laser toning
Description: Q-switched nd:YAG laser toning for melasma.
Study NCT04765930 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Q-switched nd:YAG laser toning
Description: Q-switched nd:YAG laser toning for melasma.
Study NCT00886080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation using microwave energy
Description: The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. The off-pump beating heart ablation procedure is performed according to a specific box lesion surrounding the pulmonary veins, using microwave energy. Afterwards cardiac surgery is performed as usual in both treatment arms.
Study NCT04827823 — intervention group
Intervention type: OTHER
Intervention: Retrospective evaluation of amalgam and composite restorations
Description: Multi-surface restorations that were performed by dental students and that are in function for the last five years will be clinically evaluated with mirrors and probes according to the modified USPHS criteria.
Study NCT03432143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Reviewers
Description: Intervention manuscripts will be reviewed by both a trained community member and scientific reviewers. Community reviewers will follow each journal's instructions regarding electronic access to manuscripts, use of drop-down menus and free-text boxes to address specific aspects of the review, and completion within the time frame specified by the journal.The journal editorial team will use all reviews to make decisions about acceptance, revision, or rejection of manuscripts.
Study NCT02502149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: As per arm description
Study NCT02508337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG-102
Description: Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
Study NCT02459444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powerbreathe
Description: Respiratory equipment for physiotherapy, offering to load muscles inspiratory
Study NCT02459444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: This was contemplated cinesioterapia unloaded, muscle stretching, coughing technique, sedestração and ambulation if the participant was fit.
Study NCT04494191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flibanserin 100 MG [Addyi]
Description: One tablet contains 100 mg Flibanserin
Study NCT04580875 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive surgery (laparoscopy and laparoscopic-assisted procedures) in both diagnosis and treatment of penetrating abdominal trauma in Children
Study NCT02689713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole (topical)
Description: The voriconazole (Vfend®-IV 200mg) will be applied topically to one of two skin graft sites at a concentration of 150 micromolar. Dialysates will be collected over 12 hours post-skin graft/voriconazole application for analysis in the lab of OLAM concentrations.
Study NCT02689713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Sterile Water Placebo Group
Description: Sterile water will be applied topically to the other of the two skin graft sites. Dialysates will be collected over 12 hours post-skin graft/sterile water application for analysis in the lab of OLAM concentrations.
Study NCT02290782 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Description: The surgeon and radiation oncologist should choose the largest possible suitable applicator in order to ensure that the highest possible dose is delivered to the tumor bed tissue. A dose of 20 Gy at the surface of the applicator (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 20-50 minutes, depending on the size of the applicator.~To minimize radiation dependent side effects the skin-applicator surface distance should be more than 5 mm.
Study NCT02863588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seropositive for Toxoplasma gondii
Description: blood sample
Study NCT02152930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: 1000 mg of omega-3 fatty acid ethylesters, 2 times daily, for 4 weeks, followed by 12 weeks of supervised exercise therapy in combination with 2 times daily omega-3 fatty acid supplementation.
Study NCT04440761 — intervention group
Intervention type: OTHER
Intervention: Observation only
Description: Observation only
Study NCT01379989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5
Study NCT01379989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Lipoxomal Doxorubicin (PLD)
Description: PLD 30 mg/m² i.v.
Study NCT01379989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Lipoxomal Doxorubicin (PLD)
Description: PLD 30 mg/m² i.v.
Study NCT01379989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.
Study NCT02392312 — intervention group
Intervention type: DRUG
Intervention: ATF-Fresenius S
Description: intravenous
Study NCT02901184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Treatment with Spironolactone tablets on top of standard care
Study NCT02901184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard care does not involve Spironolactone
Study NCT04547829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated recombinant human granulocyte-colony stimulating factor
Description: The dosage was determined according to the patient's weight, 100 UG / kg each time; The method of administration: subcutaneous injection; The time of administration: 24-48 hours after the end of chemotherapy, once in each chemotherapy cycle.
Study NCT02821546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's solution
Description: Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
Study NCT02821546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringer's solution
Description: Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
Study NCT02881866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Study NCT02881866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Study NCT02881866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Study NCT02881866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study NCT02459444 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy
Description: This was contemplated cinesioterapia unloaded, muscle stretching, coughing technique, sedestração and ambulation if the participant was fit.
Study NCT01582399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASKP1240
Description: intravenous(IV) infusion and subcutaneous (SC)
Study NCT01615965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tumor marker detection in lymph nodes
Description: tumor marker detection in lymph nodes by quantitative PCR
Study NCT02127021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norzyme® 40000 IU
Description: A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal
Study NCT02127021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
Study NCT00128336 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle: diet and exercise intervention
Study NCT00128336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle: diet and exercise intervention
Study NCT03000075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
Study NCT03000075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
Study NCT02508337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
Study NCT03202082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Description: Neuropsychological testing evaluates various aspects of a participants cognitive ability as well as mood.
Study NCT01880892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cricopharyngeal myotomy
Description: Endoscopic laser cricopharyngeal myotomy is one of the standard treatments for Zenker's Diverticulum. It takes about 30 minutes and at our institution requires a one night of observation in the hospital.
Study NCT03000075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for risankizumab
Description: Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
Study NCT01871519 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Balloon kyphoplasty
Description: The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.
Study NCT01706523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX209 (arbaclofen)
Description: Long-term, daily, orally-administered STX209
Study NCT02219334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NoseFrida
Description: The NoseFrida has four components, the collection container, an interchangeable filter, flexible tubing and a mouth piece. The end of the collection devise is placed on the patient's nostril, a tight seal is made via the vacuum created from suctioning of the mouth piece and secretions are easily aspirated. This device disassembles for quick disinfecting and cleaning.
Study NCT02035527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given daily PO in the a.m.
Study NCT02035527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV over 1 hour following Docetaxel administration
Study NCT02035527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV 1 hour prior to cisplatin administration
Study NCT02035527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: Correlative studies will be performed at the following time points. A total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
Study NCT02544659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamidronate disodium
Description: the patients will be administered pamidronate disodium 1 mg/kg, IV, QD, for 3 days, and every 3 month (up to month 6)
Study NCT01988675 — intervention group
Intervention type: RADIATION
Intervention: Whole Brain Irradiation
Study NCT01988675 — intervention group
Intervention type: RADIATION
Intervention: Partial Brain Irradiation
Study NCT01988675 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing
Study NCT01988675 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaire
Study NCT04347174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspension of heat killed (autoclaved) Mycobacterium w
Description: Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.
Study NCT04347174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician
Study NCT03093558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECA/Kardia
Description: Use of the ECA and Kardia daily for 30 days.
Study NCT03844802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Dry needling and exercise
Description: Deep dry needling will be applied bilaterally in the locus of active or latent myofascial trigger points of several neck shoulder muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius). The presence of active or latent myofascial trigger points will be assessed according to the diagnostic procedures described by Travell and Simons. The dry needling intervention technique will be the fast in-fast out Hong technique, with a minimum of 3 to 6 local twitch responses to be elicited.~Patients will perform a home based therapeutic neck exercises program.
Study NCT03844802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distal Dry needling and exercise
Description: Patients in this group will undergo deep dry needling at a remote spot from the locus of the myofascial trigger point. As a result no local twitch response should be elicited. As in the previous group, dry needling will be carried out in the same assessed muscles (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points, according to the diagnostic procedures described by Travell and Simons. The intervention technique chosen for these participants will be to insert the needle in a location in the same muscle, but far away (at least 1 to 1.5 cm) from the location of the myofascial trigger point. Likewise, the needle will be inserted without the intention to evoke local twitch responses. Therefore, the entry and exit of the needle will be performed in a slower fashion.~Patients will perform a home based therapeutic neck exercises program.
Study NCT03844802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham dry needling and exercise
Description: Patients in this group will undergo sham-placebo dry needling. For that purpose, placebo dry needling will be carried out in the same muscles previously described (scalene muscles, levator scapulae, splenius cervicis, multifidus cervicis and upper trapezius) with active or latent myofascial trigger points. The intervention technique will be carried out in the locus of the trigger point but using placebo needles. For this placebo group, a simulation needle procedure using a Dong Bang placebo needle, similar to the Streitberger needle, will be used. The placebo needles evoke mechanical stimulation without piercing the skin; hence, patients experience a pressure sensation similar to that of a real needle.~Patients will perform a home based therapeutic neck exercises program.
Study NCT03844802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Patients will perform a home based therapeutic neck exercises program.
Study NCT02222246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone (Standardized, weight-based dosing)
Description: Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
Study NCT02222246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate (Standardized, weight-based dosing)
Description: Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
Study NCT02222246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone (Patient Specific dosing)
Description: Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
Study NCT02222246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate (Patient Specific dosing)
Description: Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
Study NCT02064231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test A
Description: Coloplast Test A is a new ostomy appliance developed by Coloplast A/S
Study NCT02064231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test B
Description: Coloplast Test B is a newly developed ostomy appliance developed by Coloplast A/S
Study NCT02064231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Own product
Description: Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.
Study NCT02064231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test C
Description: Coloplast Test C is a new ostomy appliance developed by Coloplast A/S
Study NCT02064231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test D
Description: Coloplast Test D is a new ostomy appliance developed by Coloplast A/S
Study NCT00673868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV Specific Cytotoxic T Lymphocytes
Description: CMV Specific Cytotoxic T Lymphocytes will be infused between days 30 and 40 post-transplant at a dose ranging from 2- 5 x e5 cells/kg.